Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
56
GNMLF Quote, Financials, Valuation and Earnings
Last price:
$1.06
Seasonality move
:
-0.21%
Day range:
$1.06 - $1.06
52-week range:
$0.93 - $1.43
Dividend yield:
3.96%
P/E ratio:
11.57x
P/S ratio:
1.12x
P/B ratio:
1.72x
Volume:
--
Avg. volume:
344
1-year change:
-16.54%
Market cap:
$1B
Revenue:
$1B
EPS (TTM):
$0.09
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Genomma Lab Internacional SAB de CV has -- downside to fair value with a price target of -- per share.
GNMLF vs. S&P 500
-
Over the past 5 trading days, Genomma Lab Internacional SAB de CV has overperformed the S&P 500 by 1.23% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Genomma Lab Internacional SAB de CV does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Genomma Lab Internacional SAB de CV revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Genomma Lab Internacional SAB de CV reported revenues of $238.4M.
Earnings Growth
-
Genomma Lab Internacional SAB de CV earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Genomma Lab Internacional SAB de CV reported earnings per share of $0.02.
Enterprise value:
1.3B
EV / Invested capital:
--
Price / LTM sales:
1.12x
EV / EBIT:
6.68x
EV / Revenue:
1.42x
PEG ratio (5yr expected):
0.31x
EV / Free cash flow:
33.03x
Price / Operating cash flow:
26.06x
Enterprise value / EBITDA:
6.05x
Gross Profit (TTM):
$586.4M
Return On Assets:
7.39%
Net Income Margin (TTM):
9.66%
Return On Equity:
15.81%
Return On Invested Capital:
9.69%
Operating Margin:
20.39%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $940.4M | $986.3M | $926.2M | $269M | $238.4M | |
| Gross Profit | $569.9M | $626.9M | $586.4M | $172.8M | $152.2M | |
| Operating Income | $184.2M | $209.9M | $196.4M | $58.7M | $48.6M | |
| EBITDA | $197.7M | $225.4M | $217M | $63.4M | $53.7M | |
| Diluted EPS | $0.08 | $0.10 | $0.09 | $0.04 | $0.02 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $617.5M | $576.2M | $687.2M | $649.5M | $699.4M | |
| Total Assets | $1.1B | $1.1B | $1.3B | $1.2B | $1.3B | |
| Current Liabilities | $347.8M | $463.2M | $392M | $342.8M | $380.7M | |
| Total Liabilities | $615.1M | $542.4M | $659.3M | $630.3M | $687.5M | |
| Total Equity | $515.7M | $543.1M | $611.1M | $569M | $600.3M | |
| Total Debt | $308.4M | $200.3M | $285.7M | $312.4M | $300.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $70.3M | $93M | $66.4M | $66.7M | $15.3M | |
| Cash From Investing | -$19.6M | -$55.5M | -$25.9M | -$31.4M | -$11.4M | |
| Cash From Financing | $124.4K | -$45.7M | -$1.5M | -$4.6M | -$13.1M | |
| Free Cash Flow | $51.7M | $44.4M | $39.7M | $33.7M | $7.5M | |
GNMLF
Sector
Market Cap
$1B
$28.1M
Price % of 52-Week High
74.13%
50%
Dividend Yield
3.96%
0%
Shareholder Yield
2.89%
-1.54%
1-Year Price Total Return
-16.54%
-17.67%
Beta (5-Year)
0.121
0.503
Dividend yield:
3.96%
Annualized payout:
$0.04
Payout ratio:
44.92%
Growth streak:
1 years
Technicals
8-day SMA
Sell
Level
$1.06
200-day SMA
Sell
Level
$1.15
Bollinger Bands (100)
Sell
Level
0.96 - 1.16
Chaikin Money Flow
Sell
Level
-24.7K
20-day SMA
Buy
Level
$1.02
Relative Strength Index (RSI14)
Buy
Level
81.06
ADX Line
Buy
Level
45.5
Williams %R
Sell
Level
0
50-day SMA
Buy
Level
$0.99
MACD (12, 26)
Buy
Level
0.02
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Sell
Level
-3.6K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.8173)
Buy
CA Score
(Annual)
Level (0.5303)
Buy
Beneish M-Score
(Annual)
Level (-2.5569)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.5477)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Genomma Lab Internacional SAB de CV engages in the development, manufacturing and marketing of pharmaceutical, beauty and personal care products. The company was founded by Rodrigo Alonso Herrera Aspra on October 30, 1996 and is headquartered in Mexico City, Mexico.
Stock Forecast FAQ
In the current month, GNMLF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GNMLF average analyst price target in the past 3 months is --.
-
Where Will Genomma Lab Internacional SAB de CV Stock Be In 1 Year?
According to analysts, the consensus estimate is that Genomma Lab Internacional SAB de CV share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Genomma Lab Internacional SAB de CV?
Analysts are divided on their view about Genomma Lab Internacional SAB de CV share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Genomma Lab Internacional SAB de CV is a Sell and believe this share price will rise from its current level to --.
-
What Is Genomma Lab Internacional SAB de CV's Price Target?
The price target for Genomma Lab Internacional SAB de CV over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GNMLF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Genomma Lab Internacional SAB de CV is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of GNMLF?
You can purchase shares of Genomma Lab Internacional SAB de CV via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Genomma Lab Internacional SAB de CV shares.
-
What Is The Genomma Lab Internacional SAB de CV Share Price Today?
Genomma Lab Internacional SAB de CV was last trading at $1.06 per share. This represents the most recent stock quote for Genomma Lab Internacional SAB de CV. Yesterday, Genomma Lab Internacional SAB de CV closed at $1.06 per share.
-
How To Buy Genomma Lab Internacional SAB de CV Stock Online?
In order to purchase Genomma Lab Internacional SAB de CV stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get GNMLF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GNMLF
Sector
P/E ratio
11.57x
23.88x
PEG ratio
0.31x
-0.01x
P/B ratio
1.72x
1.82x
Price / LTM sales
1.12x
1.59x
Growth Metrics
GNMLF
Sector
Revenue growth
-11.37%
4.73%
Earnings growth
-35.23%
11.11%
Revenue (5-year growth)
8.98%
6.46%
Earnings forecast
--
-$0.18
Profitability
GNMLF
Sector
Profitability FY 2024
$650.9M
$3.6M
Return on invested capital
9.69%
-31.77%
Return on assets
7.39%
-28.18%
Return on equity
15.81%
-37.47%
Earnings Date
Last Earnings Date
Oct
22
Next Earnings Date
Feb
25
Estimated Next Earnings Date
Jan
21
Balance Sheet
GNMLF
Sector
Total cash
$123.6M
$26.3M
Short term investments
$4.3M
$26M
Total assets
$1.1B
$76.9M
Long term debt
$300.5M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 2
Corcept Therapeutics, Inc. [CORT] is up 9.68% over the past day.
Sell
47
ASTS alert for Jan 2
AST Spacemobile, Inc. [ASTS] is up 14.94% over the past day.
Sell
45
BIDU alert for Jan 2
Baidu, Inc. [BIDU] is up 15.01% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
